Bivalirudin in Primary PCI: Can Its Glory Being Restored?  

作　　者：Yang Li Yi Li Gregg W.Stone Yaling Han 

机构地区：[1]Cardiovascular Research Institute and Department of Cardiology,General Hospital of Northern Theater Command,Shenyang,Liaoning 110016,China [2]Icahn School of Medicine at Mount Sinai,Mount Sinai Heart and the Cardiovascular Research Foundation,New York,New York 10029-5674,USA.

出　　处：《Cardiology Discovery》2021年第3期179-194,共16页心血管病探索（英文）

基　　金：supported by the Key Research and Development Program of Liaoning Province(2020JH 2/10300167);Project of Science and Technology Plan of Shenyang(19-112-4-051);Cardiacare Sponsored Optimizing Antithrombotic Research Fund(BJUHFCSOARF201901-06).

摘　　要：Intravenous anticoagulant therapy is critical to prevent ischemic recurrences and complications without increasing the risk of bleeding in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). It includes the indirect thrombin inhibitor heparins and the direct thrombin inhibitor bivalirudin. However, the ideal anticoagulant for patients undergoing PPCI remains controversial. In this review, we provide an overview of currently available anticoagulant therapies used in STEMI patients undergoing PPCI, including describing the rationale for their use, pivotal clinical trial data, and treatment recommendations of guidelines, providing much-needed clarity to guide the selection of the safest and most effective anticoagulant regimens for PPCI.

关 键 词：BIVALIRUDIN HEPARIN ST-segment elevation myocardial infarction Primary percutaneous coronary intervention 

分 类 号：R54[医药卫生—心血管疾病]